{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pfam:PF09793",
      "entity_text" : "AD",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ18249",
      "entity_text" : "bryostatin I",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "It is therefore possible that experimental doses of bryostatin I lead to PKCepsilon downregulation in the AD mouse or patient brain, thus reducing the activated pool of pathologically elevated Ephexin5 in AD and ameliorating the synaptic loss observed in AD.",
  "reading_complete" : "2020-08-08T18:47:08Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T18:42:19Z",
  "trigger" : "reducing",
  "evidence" : [ "bryostatin I lead to PKCepsilon downregulation in the AD mouse or patient brain, thus reducing the activated pool of pathologically elevated Ephexin5 in AD" ],
  "pmc_id" : "6371982",
  "score" : 0
}